DOCSLIB.ORG

2017 ANNUAL REPORT | Translating SCIENCE • Transforming LIVES OUR COMMITMENT Make Every Day Count at PTC, Patients Are at the Center of Everything We Do

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

20 YEARS OF COMMITMENT 2017 ANNUAL REPORT | Translating SCIENCE • Transforming LIVES OUR COMMITMENT Make every day count At PTC, patients are at the center of everything we do. We have the opportunity to support patients and families living with rare disorders through their journey. We know that every day matters and we are committed to making a difference. OUR SCIENCE Our scientists are finding new ways to regulate biology to control disease We have several scientific research platforms focused on modulating protein expression within the cell that we believe have the potential to address many rare genetic disorders. OUR PEOPLE Care for each other, our community, and for the needs of our patients At PTC, we are looking at drug discovery and development in a whole new light, bringing new technologies and approaches to developing medicines for patients living with rare disorders and cancer. We strive every day to be better than we were the day before. At PTC Therapeutics, it is our mission to provide access to best-in-class treatments for patients who have an unmet need. We are a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Founded 20 years ago, PTC Therapeutics has successfully launched two rare disorder products and has a global commercial footprint. This success is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. As we celebrate our 20th year of bringing innovative therapies to patients affected by rare disorders, we reflect on our unwavering commitment to our patients, our science and our employees. We have continually reinvested in our innovative science platforms adding to our robust pipeline in rare disorders as well commercializing two products for the treatment for Duchenne muscular dystrophy. Building on this foundation, we look forward to the next 20 years remaining loyal to our culture and our commitment to make every day count for patients. 2 3 A Patient’s Story “ If I could say one thing to PTC it would be this: Thank you for not giving up and throwing in the towel. It truly is working. Everything he (Benjamin) can do now is BENJAMIN RODRIGUEZ because of ataluren.” -Diana Rodriguez Birthday parties shouldn’t be a reason to worry for any parent but when Diana Rodriguez and her son were invited It was an achievement she never thought possible. Since to one at a new community park, the mother of two July 2016, Benjamin has been enrolled in a clinical trial paused. Benjamin, 5, has Duchenne muscular dystrophy and takes ataluren. His parents soon noticed a difference and outdoor parties are prime opportunities for kids to run when Benjamin, who use to just walk fast, began to run. around and, well, be kids. Then, one day, he jumped. He now attends school and Diana often feared her son would be inadvertently knocked participates in physical education classes, running, and down and hurt or feel left out if he couldn’t participate in playing soccer, just like any other 5-year-old. an activity. Adding to her angst was the party venue: A new “I definitely didn’t think he’d be running around.” Diana community park full of playground equipment that could said. “He still has all this energy and now he uses it to prove very challenging for a young boy with DMD. climb on things and run around. And, he keeps asking to But on this sunny Florida day in February, it didn’t take go back to the playground.” long for Diana to realize her worries were unfounded. Ben It’s a remarkable improvement for a little boy who, walked up to a new structure and started to climb on it. according to his mom, remembers there was a time he Later, she saw him on a zipline. couldn’t do things like other boys. That’s not the case “He was feeling good about himself,” she said. “It had to anymore for Benjamin, who loves Star Wars and has his do with his confidence. I could see it, and that meant I own light saber. could step back a bit because he was showing me that he “We are so lucky to have ataluren,” Diana said. “If I could do it. He was OK.” could say one thing to PTC it would be this: Thank you Hours later, Diana logged onto her Twitter account and for not giving up and throwing in the towel. It truly is announced: Today was the first time we went to the park working. Everything he (Benjamin) can do now is because and Benjamin didn’t hesitate to play. of ataluren.” 1998 1999 • PTC incorporated • Tularik collaboration Milestones • Series A&B financing • Initiate nonsense • PTC124 (ataluren/Translarna™) discovery suppression program 2 3 A Scientist’s Story ANU BHATTACHARYYA, DIRECTOR OF BIOLOGY PTC Just because a collaboration ends doesn’t mean a scientist stops thinking about it, and Anu Bhattacharyya couldn’t stop thinking about the brain and the diseases that affect it. She wanted to know more about the mechanisms that lead to neurological disorders so she invested in an atlas “ This is a very exciting time for emerging of the brain and studied it to learn more about the organ’s research in the Huntington’s disease different regions and why they break down in some people. community, and PTC is committed to The more she learned, the stronger her passion grew. following the science to discover and She started to wonder whether she could harness her develop novel small molecule treatments passion into something that might help people afflicted with Huntington’s disease, a fatal genetic disorder that for patients with rare diseases.” causes the progressive breakdown of nerve cells in the -Anu Bhattacharyya brain. It deteriorates a person’s physical and mental abilities during their prime adult years and has no cure. With that thought in mind and a business case in hand, she walked into her boss’ office to pitch her idea, confident that “This is a very exciting time for emerging research in the it was the right thing to do. He agreed. Huntington’s disease community, and PTC is committed to following the science to discover and develop novel Go for it, he told her. small molecule treatments for patients with rare diseases,” She got support from PTC’s leadership team even Bhattacharyya said. though resources were scarce and the company didn’t She built a business case that she believed would prove have a Huntington’s program. Combine that endorsement that a Huntington’s program could fit into PTC’s business with the unmet medical need and the result is a recipe goals and strategy of innovation, and, eventually, its that led to PTC’s Huntington’s disease program, which splicing platform. recently announced a research collaboration with the CHDI Foundation. “Huntington’s disease is a rare genetic disorder so it falls right into PTC’s sweet spot,” she said. “One appealing “When I started to build the rationale for the discovery feature of Huntington’s disease is that it’s a monogenic and development of this program, I didn’t know the disorder and the key culprit is a single expansion mutation Huntington’s research and patient community,” in the huntingtin gene. That makes it an easier problem to Bhattacharyya said. “Now, our relationships are strong tackle; we know the key cause of the disease, so targeting and our discovery program is showing great promise to the expression of huntingtin is the most direct and efficient deliver an oral medication for Huntington’s disease. way of targeting Huntington’s disease.” That is what can be accomplished at PTC.” 2000 2001 2002 • Moved into New Jersey • Series D financing • PTC124 (ataluren/Translarna™): corporate headquarters Lead optimization • Series C financing 4 5 Strong commercial growth Translarna™ & Emflaza™ Duchenne Net Sales ($ in millions) “ Every day, PTC scientists 180 dedicate their efforts to TM Emflaza finding new and better (deflazacort) treatments for people with 144 TM rare disorders and oncology. Translarna (ataluren) We take special pride in the innovation seen throughout 108 our pipeline and that’s because we developed it in-house; it’s a reflection 72 of our hard work and dedication to positively impact the lives of patients 36 and their families.” Dr. Nikolai Naryshkin VP, Biology 0 2014 2015 2016 2017 2003 2004 2005 • Facility expansion • Series E financing • Facility expansion • NIH STTR grant: Nonsense suppression • Series E-2 financing • PTC124 (ataluren/Translarna™) IND filed • PTC124 (ataluren/Translarna™) • PTC124 (ataluren/Translarna™) Phase 1 Phase 2a (004) Duchenne healthy volunteer study 4 5 Our Pipeline PRODUCT/ DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL PLATFORM ORPHAN GENETIC DISORDERS EMFLAZATM DMD (deflazacort) TM Translarna DMD (ataluren) nonsense readthrough * Aniridia Dravet / CDKL5 Next Generation nonsense readthrough SMA SMA alternative splicing Huntington’s HD alternative splicing Familial Dysautonomia FD alternative splicing ONCOLOGY PTC596 BMI1 tumor stem cell targeting DHODH (1) Orphan Oncology DHODH (2) *Marketing authorization has specific obligation to conduct additional nmDMD trial and requires annual renewal following reassessment by EMA 2006 2007 2008 • SMA Foundation Grant • CELG Equity investment & collaboration • (ataluren/Translarna™) • FDA Grant: PTC124 (ataluren/Translarna™) • Nature publication – PTC124 Phase 2b (007) Duchenne Duchenne (ataluren/Translarna™) nonsense platform • Fight SMA grant • JCP publication – HV study – PTC124 (ataluren/Translarna™) • SMA Foundation grant 6 7 A Message to Our Shareholders This acquisition was a strategic opportunity for PTC; with our long-standing partnership with the Duchenne commu- nity, we were uniquely positioned to bring this medicine to patients in the U.S.
Recommended publications
  • Spinraza™ (Nusinersen)

    Spinraza™ (Nusinersen)

    Spinraza™ (nusinersen) (Intrathecal) Document Number: IC-0291 Last Review Date: 08/03/2021 Date of Origin: 01/31/2017 Dates Reviewed: 01/2017, 02/2017, 01/2018, 08/2018, 06/2019, 08/2020, 08/2021 I. Length of Authorization Coverage will be provided annually and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Loading: 1 vial on D1, D15, D29, and D59 • Maintenance: 1 vial every 112 days B. Max Units (per dose and over time) [HCPCS Unit]: • Loading: 120 billable units on D1, D15, D29, and D59 • Maintenance: 120 billable units every 112 days III. Initial Approval Criteria1-12 • Submission of medical records related to the medical necessity criteria is REQUIRED on all requests for authorizations. Records will be reviewed at the time of submission. Please provide documentation via direct upload through the PA web portal or by fax. Coverage is provided in the following conditions: Spinal Muscular Atrophy (SMA) † Ф • Patient must not have previously received treatment with SMA gene therapy (i.e., onasemnogene abeparvovec-xioi); AND • Patient will not use in combination with other agents for SMA (e.g., onasemnogene abeparvovec, risdiplam, etc.); AND • Patient must not have advanced disease (complete limb paralysis, permanent ventilation support, etc.); AND Moda Health Plan, Inc. Medical Necessity Criteria Page 1/5 Proprietary & Confidential © 2021 Magellan Health, Inc. • Patient must have the following laboratory tests at baseline and prior to each administration*: platelet count, prothrombin time; activated
  • Spinraza® (Nusinersen)

    Spinraza® (Nusinersen)

    UnitedHealthcare® Commercial Medical Benefit Drug Policy Spinraza® (Nusinersen) Policy Number: 2021D0059I Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale ....................................................................... 1 • Spinraza® (Nusinersen) Documentation Requirements ...................................................... 3 Applicable Codes .......................................................................... 3 Background.................................................................................... 4 Benefit Considerations .................................................................. 5 Clinical Evidence ........................................................................... 5 U.S. Food and Drug Administration ............................................. 8 References ..................................................................................... 9 Policy History/Revision Information ........................................... 10 Instructions for Use ..................................................................... 11 Coverage Rationale See Benefit Considerations Spinraza® (nusinersen) is proven and medically necessary for the treatment of spinal muscular atrophy (SMA) in patients who meet all of the following criteria: 1-4,22,23 Initial Therapy Diagnosis of spinal muscular atrophy by, or in consultation with, a neurologist with expertise in the diagnosis of SMA; and Submission of medical records (e.g., chart notes, laboratory values)
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1

    DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1

    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
  • Duchenne Muscular Dystrophy (DMD) Agents

    Duchenne Muscular Dystrophy (DMD) Agents

    Therapeutic Class Overview Duchenne muscular dystrophy (DMD) Agents INTRODUCTION • Duchenne muscular dystrophy (DMD) is 1 of 4 conditions known as dystrophinopathies, which are inherited, X-linked myopathic disorders due to a defect in the dystrophin gene that results in the primary pathologic process of muscle fiber degradation. The hallmark symptom is progressive weakness (Darras 2018[a], Darras 2018[b], Muscular Dystrophy Association [MDA] 2019). The other 3 conditions include: Becker muscular dystrophy (BMD), which is a mild form of DMD; an intermediate presentation between BMD and DMD; and DMD-associated dilated cardiomyopathy, which has little or no clinical ○ skeletal or muscle disease (MDA 2019). • DMD symptom onset is in early childhood, usually between the ages of 2 and 3 years old. The proximal muscles are affected first, followed by the distal limb muscles. Generally, the lower external muscles will be affected before the upper. The affected child may have difficulties jumping, walking, and running (MDA 2019). • The prevalence of DMD ranges from 1 to 2 per 10,000 live male births; female-manifesting carriers are rarer, but can present with a range of symptoms that vary in their severities (Birnkrant et al 2018, Darras 2018[a], Emflaza Food and Drug Administration [FDA] Medical Review 2017). • The clinical course and lifespan of patients with DMD is relatively short. Individuals are usually confined to a wheelchair by age 13, and many die in their late teens or twenties from respiratory insufficiency or cardiomyopathy. Although survival until adulthood is more common now, very few patients survive past the 3rd decade (Darras 2018[a]).
  • New Brunswick Drug Plans Formulary

    New Brunswick Drug Plans Formulary

    New Brunswick Drug Plans Formulary August 2019 Administered by Medavie Blue Cross on Behalf of the Government of New Brunswick TABLE OF CONTENTS Page Introduction.............................................................................................................................................I New Brunswick Drug Plans....................................................................................................................II Exclusions............................................................................................................................................IV Legend..................................................................................................................................................V Anatomical Therapeutic Chemical (ATC) Classification of Drugs A Alimentary Tract and Metabolism 1 B Blood and Blood Forming Organs 23 C Cardiovascular System 31 D Dermatologicals 81 G Genito Urinary System and Sex Hormones 89 H Systemic Hormonal Preparations excluding Sex Hormones 100 J Antiinfectives for Systemic Use 107 L Antineoplastic and Immunomodulating Agents 129 M Musculo-Skeletal System 147 N Nervous System 156 P Antiparasitic Products, Insecticides and Repellants 223 R Respiratory System 225 S Sensory Organs 234 V Various 240 Appendices I-A Abbreviations of Dosage forms.....................................................................A - 1 I-B Abbreviations of Routes................................................................................A - 4 I-C Abbreviations of Units...................................................................................A
  • Circulating Biomarkers in Neuromuscular Disorders: What Is Known, What Is New

    Circulating Biomarkers in Neuromuscular Disorders: What Is Known, What Is New

    biomolecules Review Circulating Biomarkers in Neuromuscular Disorders: What Is Known, What Is New Andrea Barp 1,* , Amanda Ferrero 1, Silvia Casagrande 1,2 , Roberta Morini 1 and Riccardo Zuccarino 1 1 NeuroMuscular Omnicentre (NeMO) Trento, Villa Rosa Hospital, Via Spolverine 84, 38057 Pergine Valsugana, Italy; [email protected] (A.F.); [email protected] (S.C.); [email protected] (R.M.); [email protected] (R.Z.) 2 Department of Neurosciences, Drug and Child Health, University of Florence, Largo Brambilla 3, 50134 Florence, Italy * Correspondence: [email protected] Abstract: The urgent need for new therapies for some devastating neuromuscular diseases (NMDs), such as Duchenne muscular dystrophy or amyotrophic lateral sclerosis, has led to an intense search for new potential biomarkers. Biomarkers can be classified based on their clinical value into different categories: diagnostic biomarkers confirm the presence of a specific disease, prognostic biomarkers provide information about disease course, and therapeutic biomarkers are designed to predict or measure treatment response. Circulating biomarkers, as opposed to instrumental/invasive ones (e.g., muscle MRI or nerve ultrasound, muscle or nerve biopsy), are generally easier to access and less “time-consuming”. In addition to well-known creatine kinase, other promising molecules seem to be candidate biomarkers to improve the diagnosis, prognosis and prediction of therapeutic response, such as antibodies, neurofilaments, and microRNAs. However, there are some criticalities that can complicate their application: variability during the day, stability, and reliable performance metrics Citation: Barp, A.; Ferrero, A.; (e.g., accuracy, precision and reproducibility) across laboratories. In the present review, we discuss Casagrande, S.; Morini, R.; Zuccarino, the application of biochemical biomarkers (both validated and emerging) in the most common NMDs R.
  • The Use of Ataluren in the Effective Management of Duchenne Muscular Dystrophy

    The Use of Ataluren in the Effective Management of Duchenne Muscular Dystrophy

    Review Neuromuscular Diseases Early Diagnosis and Treatment – The Use of Ataluren in the Effective Management of Duchenne Muscular Dystrophy Eugenio Mercuri,1 Ros Quinlivan2 and Sylvie Tuffery-Giraud3 1. Catholic University, Rome, Italy; 2. Great Ormond Street Hospital and National Hospital for Neurology and Neurosurgery, London, UK; 3. Laboratory of Genetics of Rare Diseases (LGMR), University of Montpellier, Montpellier, France DOI: https://doi.org/10.17925/ENR.2018.13.1.31 he understanding of the natural history of Duchenne muscular dystrophy (DMD) is increasing rapidly and new treatments are emerging that have the potential to substantially improve the prognosis for patients with this disabling and life-shortening disease. For many, Thowever, there is a long delay between the appearance of symptoms and DMD diagnosis, which reduces the possibility of successful treatment. DMD results from mutations in the large dystrophin gene of which one-third are de novo mutations and two-thirds are inherited from a female carrier. Roughly 75% of mutations are large rearrangements and 25% are point mutations. Certain deletions and nonsense mutations can be treated whereas many other mutations cannot currently be treated. This emphasises the need for early genetic testing to identify the mutation, guide treatment and inform genetic counselling. Treatments for DMD include corticosteroids and more recently, ataluren has been approved in Europe, the first disease-modifying therapy for treating DMD caused by nonsense mutations. The use of ataluren in DMD is supported by positive results from phase IIb and phase III studies in which the treatment produced marked improvements in the 6-minute walk test, timed function tests such as the 10 m walk/run test and the 4-stair ascent/descent test compared with placebo.
  • For Cystic Fibrosis (Review)

    For Cystic Fibrosis (Review)

    Cochrane Database of Systematic Reviews Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis (Review) Aslam AA, Higgins C, Sinha IP, Southern KW Aslam AA, Higgins C, Sinha IP, Southern KW. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD012040. DOI: 10.1002/14651858.CD012040.pub2. www.cochranelibrary.com Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 7 OBJECTIVES ..................................... 8 METHODS ...................................... 8 RESULTS....................................... 12 Figure1. ..................................... 13 Figure2. ..................................... 16 DISCUSSION ..................................... 20 AUTHORS’CONCLUSIONS . 22 ACKNOWLEDGEMENTS . 22 REFERENCES ..................................... 23 CHARACTERISTICSOFSTUDIES . 26 DATAANDANALYSES. 33 Analysis 1.1. Comparison 1 Ataluren versus placebo, Outcome 1 FEV - mean relative change from baseline. 35 Analysis 1.2. Comparison 1
  • Ataluren Stimulates Ribosomal Selection of Near-Cognate Trnas to Promote Nonsense Suppression

    Ataluren Stimulates Ribosomal Selection of Near-Cognate Trnas to Promote Nonsense Suppression

    Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression Bijoyita Roya,b,1, Westley J. Friesenb,1, Yuki Tomizawab, John D. Leszykc, Jin Zhuob, Briana Johnsonb, Jumana Dakkab, Christopher R. Trottab, Xiaojiao Xueb,d,e, Venkateshwar Mutyame,f, Kim M. Keelingd,e, James A. Mobleyg, Steven M. Rowee,f, David M. Bedwelld,e, Ellen M. Welchb, and Allan Jacobsona,2 aDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655-0122; bPTC Therapeutics Inc., South Plainfield, NJ 07080; cDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01655-0122; dDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294; eGregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294; fDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294; and gDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294 Edited by Rachel Green, Johns Hopkins University, Baltimore, MD, and approved September 6, 2016 (received for review April 1, 2016) A premature termination codon (PTC) in the ORF of an mRNA promote therapeutic nonsense suppression (1, 3). To date, ataluren generally leads to production of a truncated polypeptide, accelerated has been shown to restore function to more than 20 different degradation of the mRNA, and depression of overall mRNA ex- disease-specific or reporter nonsense alleles in systems ranging in pression. Accordingly, nonsense mutations cause some of the most complexity from in vitro translation to cell culture to mouse models severe forms of inherited disorders. The small-molecule drug ataluren and human patients (1, 3–14).
  • Annexes to the Annual Report of the European Medicines Agency 2014

    Annexes to the Annual Report of the European Medicines Agency 2014

    Annexes to the annual report of the European Medicines Agency 2014 Table of contents Annex 1 – Members of the Management Board ............................................................................. 2 Annex 2 – Members of the Committee for Medicinal Products for Human Use ................................... 4 Annex 3 – Members of the Pharmacovigilance Risk Assessment Committee ...................................... 6 Annex 4 – Members of the Committee for Medicinal Products for Veterinary Use ............................... 8 Annex 5 – Members of the Committee on Orphan Medicinal Products ............................................ 10 Annex 6 – Members of the Committee on Herbal Medicinal Products .............................................. 12 Annex 07 – Committee for Advanced Therapies .......................................................................... 14 Annex 8 – Members of the Paediatric Committee ........................................................................ 16 Annex 9 – Working parties and working groups .......................................................................... 18 Annex 10 – CHMP opinions in 2014 on medicinal products for human use ...................................... 22 Annex 11 – CVMP opinions in 2014 on medicinal products for veterinary use .................................. 36 Annex 12 – COMP opinions in 2014 on designation of orphan medicinal products ............................ 41 Annex 13 – HMPC European Union herbal monographs in 2014....................................................
  • Rxoutlook® 1St Quarter 2019

    Rxoutlook® 1St Quarter 2019

    ® RxOutlook 1st Quarter 2020 optum.com/optumrx a RxOutlook 1st Quarter 2020 Orphan drugs continue to feature prominently in the drug development pipeline In 1983 the Orphan Drug Act was signed into law. Thirty seven years later, what was initially envisioned as a minor category of drugs has become a major part of the drug development pipeline. The Orphan Drug Act was passed by the United States Congress in 1983 in order to spur drug development for rare conditions with high unmet need. The legislation provided financial incentives to manufacturers if they could demonstrate that the target population for their drug consisted of fewer than 200,000 persons in the United States, or that there was no reasonable expectation that commercial sales would be sufficient to recoup the developmental costs associated with the drug. These “Orphan Drug” approvals have become increasingly common over the last two decades. In 2000, two of the 27 (7%) new drugs approved by the FDA had Orphan Designation, whereas in 2019, 20 of the 48 new drugs (42%) approved by the FDA had Orphan Designation. Since the passage of the Orphan Drug Act, 37 years ago, additional regulations and FDA designations have been implemented in an attempt to further expedite drug development for certain serious and life threatening conditions. Drugs with a Fast Track designation can use Phase 2 clinical trials to support FDA approval. Drugs with Breakthrough Therapy designation can use alternative clinical trial designs instead of the traditional randomized, double-blind, placebo-controlled trial. Additionally, drugs may be approved via the Accelerated Approval pathway using surrogate endpoints in clinical trials rather than clinical outcomes.
  • Corporate Medical Policy

    Corporate Medical Policy

    Corporate Medical Policy Nusinersen (Spinraza™) File Name: nusinersen_spinraza Origination: 03/2017 Last CAP Review: 10/2020 Next CAP Review: 10/2021 Last Review: 10/2020 Description of Procedure or Service Spinal muscular atrophy (SMA) is an inherited disorder caused by homozygous deletions or variants in the SMN1 gene. As a consequence of low levels of SMN1 protein, the motor neurons in spinal cord degenerate, resulting in atrophy of the voluntary muscles of the limbs and trunk. Nusinersen is a synthetic antisense oligonucleotide designed to bind to a specific sequence in exon 7 of the SMN2 transcript causing the inclusion of exon 7 in the SMN2 transcript, leading to production of full length functional SMN2 protein, which demonstrates similarity to SMN1. SPINAL MUSCULAR ATROPHY Spinal muscular atrophy (SMA) is a rare autosomal recessive genetic disorder caused by homozygous deletions or variants in the SMN1 gene in chromosome 5. This gene is responsible for producing the “survival of motor neuron” protein (SMN1). As a consequence of absent or low levels of this protein, the motoneurons in the spinal cord degenerate, resulting in atrophy of the voluntary muscles of the limbs and trunk. During early development, these muscles are necessary for crawling, walking, sitting up, and head control. The more severe types of SMA can also affect muscles involved in feeding, swallowing, and breathing. The exact role of the SMN protein in motoneurons has not been completely elucidated and levels of the SMN protein required for optimal functioning are unknown. SMN2 is a nearly identical modifying gene capable of producing compensatory SMN protein.